CDKN2C and prostate carcinoma: CDKN2C has previously been described as a candidate tumour suppressor gene, but it has been observed in many types of cancer, including leukaemia [51] and prostate cancer [52], as well as malignant meningiomas and oligodendrogliomas [53,54].